Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer-Reference-Cited by-同舟云学术

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

Published:2008-10 Issue:10 Volume:9 Page:962-972
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Linardou Helena,Dahabreh Issa J,Kanaloupiti Dimitra,Siannis Fotios,Bafaloukos Dimitrios,Kosmidis Paris,Papadimitriou Christos A,Murray Samuel

Publisher

Elsevier BV

Subject

Oncology

Reference90 articles.

1. Gefitinib-a novel targeted approach to treating cancer;Herbst;Nat Rev Cancer,2004

2. Epidermal growth factor receptor (EGFR) signaling in cancer;Normanno;Gene,2006

3. EGFR and cancer prognosis;Nicholson;Eur J Cancer,2001

4. Epidermal growth factor receptor: mechanisms of activation and signaling;Jorissen;Exp Cell Res,2003

5. Epidermal growth factor targeting in cancer;Mendelshon;Semin Oncol,2006

Cited by 659 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. A pan-KRAS degrader for the treatment of KRAS-mutant cancers;Cell Discovery;2024-06-28

3. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy;Expert Opinion on Investigational Drugs;2024-05-22

4. Physiologically driven nanodrug delivery system for targeted lung cancer treatment;Exploration of Medicine;2024-04-25

5. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma;Nature Communications;2024-04-23